Susquehanna International Group, LLP Aveo Pharmaceuticals, Inc. Transaction History

Susquehanna International Group, LLP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$8.48 - $14.97 $3.22 Million - $5.69 Million	380,259 Added 645.6%	439,159 $6.57 Million
Q3 2022 Nov 14, 2022	BUY	$6.61 - $8.72 $389,329 - $513,608	58,900 New	58,900 $485,000
Q1 2022 May 16, 2022	SELL	$3.15 - $6.01 $671,091 - $1.28 Million	-213,045 Reduced 51.71%	198,953 $1.11 Million
Q4 2021 Feb 14, 2022	SELL	$4.69 - $7.4 $769 - $1,213	-164 Reduced 0.04%	411,998 $1.93 Million
Q3 2021 Nov 15, 2021	BUY	$5.12 - $6.89 $804,311 - $1.08 Million	157,092 Added 61.59%	412,162 $2.55 Million
Q2 2021 Aug 11, 2021	BUY	$6.21 - $7.45 $1.47 Million - $1.76 Million	236,359 Added 1263.21%	255,070 $1.68 Million
Q1 2021 May 17, 2021	SELL	$5.97 - $15.28 $428,037 - $1.1 Million	-71,698 Reduced 79.3%	18,711 $137,000
Q4 2020 Feb 16, 2021	SELL	$5.08 - $6.68 $91,612 - $120,467	-18,034 Reduced 16.63%	90,409 $522,000
Q3 2020 Nov 16, 2020	BUY	$4.16 - $6.26 $44,046 - $66,280	10,588 Added 10.82%	108,443 $644,000
Q2 2020 Aug 14, 2020	BUY	$3.47 - $9.99 $149,012 - $429,000	42,943 Added 78.2%	97,855 $504,000
Q1 2020 May 15, 2020	BUY	$2.6 - $6.9 $142,771 - $378,892	54,912 New	54,912 $199,000

Ticker AVEO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,676,000
Description
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the ...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.